Developmental Biology Program
The Danwei Huangfu Lab
QSER1 protects DNA methylation valleys from de novo methylation. Dixon G, Pan H, Yang D, Rosen BP, Jashari T, Verma N, Pulecio J, Caspi I, Lee K, Stransky S, Glezer A, Liu C, Rivas M, Kumar R, Lan Y, Torregroza I, He C, Sidoli S, Evans T, Elemento O, Huangfu D. Science. 2021 Apr 9;372(6538):eabd0875. doi: 10.1126/science.abd0875. [PMID: 33833093]
FOXA2 Is Required for Enhancer Priming during Pancreatic Differentiation. Lee K, Cho H, Rickert RW, Li QV, Pulecio J, Leslie CS, Huangfu D. Cell Rep. 2019;28(2):382-393.e7.
Genome-scale screens identify JNK-JUN signaling as a barrier for pluripotency exit and endoderm differentiation. Li QV, Dixon G, Verma N, Rosen BP, Gordillo M, Luo R, Xu C, Wang Q, Soh CL, Yang D, Crespo M, Shukla A, Xiang Q, Dündar F, Zumbo P, Witkin M, Koche R, Betel D, Chen S, Massagué J, Garippa R, Evans T, Beer MA, Huangfu D. Nat Genet. 2019;51(6):999-1010.
DICER1 Is Essential for Self-Renewal of Human Embryonic Stem Cells. Teijeiro V, Yang D, Majumdar S, González F, Rickert RW, Xu C, Koche R, Verma N, Lai EC, Huangfu D. Stem Cell Reports. 2018;11(3):616-625.
TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells. Verma N, Pan H, Doré LC, Shukla A, Li QV, Pelham-Webb B, Teijeiro V, González F, Krivtsov A, Chang CJ, Papapetrou EP, He C, Elemento O, Huangfu D. Nat Genet. 2018;50(1):83-95.
Danwei Huangfu, PhD
- The Huangfu laboratory uses human pluripotent stem cells (hPSCs) as a powerful genetic model to interrogate the transcriptional and epigenetic mechanisms underlying cell fate decisions in development and disease.
- PhD, Cornell University, Weill Graduate School of Medical Sciences
- BS, Fudan University
- PhD, Columbia University
- BS, University of Chicago
- Basil O’Connor Scholar, March of Dimes Birth Defects Foundation (2012-2014)
- Louis V. Gerstner, Jr. Young Investigators Award, Memorial Sloan Kettering Cancer Center (2011-2014)
- Award from Harvard Catalyst & InnoCentive for the Ideation Challenge on “What Do We Not Know to Cure Type 1 Diabetes” (2010)
- Helen Hay Whitney Postdoctoral Fellowship (2006-2009)
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Danwei Huangfu discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.